Arcutis Biotherapeutics, Inc. ARQT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed October 28, 2025, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s EBITDA margin?
- Arcutis Biotherapeutics, Inc. (ARQT) reported EBITDA margin of -10.5% in Q3 2025.
- How has Arcutis Biotherapeutics, Inc.'s EBITDA margin changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s EBITDA margin increased by 91.8% year-over-year, from -129.3% to -10.5%.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s EBITDA margin?
- Over 2 years (2022 to 2024), Arcutis Biotherapeutics, Inc.'s EBITDA margin has grown at a -91.1% compound annual growth rate (CAGR), from -8,157.7% to -64%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.